Question special
Chief Resident

Medication deliver to eligible pts in real world is a challenge while the dose-titration and optimization to goal doses used in clinical trials is yet another one.

Despite multiple studies showing cost-effectiveness of HF medications across many parts of the world, the probelem with medication utilization and dose optimization continues to persist. This not only limits the true benefits of the medicine but also without goal doses that have demonstrated benefit in clinical trials, we are not sure what we are achieving even if pts are on those medications.

What is the authors take, being experts in this field, on bridging the gap between trial world and the real world. What measures can we as general practitioners or advance cardiology providers implement?